.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
US Department of Justice
Julphar
Farmers Insurance
Daiichi Sankyo
Mallinckrodt
Covington
Teva
Moodys
McKesson

Generated: July 21, 2017

DrugPatentWatch Database Preview

IMITREX Drug Profile

« Back to Dashboard

What is the patent landscape for Imitrex, and when can generic versions of Imitrex launch?

Imitrex is a drug marketed by Glaxosmithkline and is included in three NDAs.

The generic ingredient in IMITREX is sumatriptan succinate. There are twenty-three drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for Tradename: IMITREX

Patents:0
Applicants:1
NDAs:3
Suppliers / Packagers: see list7
Bulk Api Vendors: see list36
Clinical Trials: see list21
Patent Applications: see list1,096
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:IMITREX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-001Aug 26, 1997ABRXYesYes► Subscribe► Subscribe
Glaxosmithkline
IMITREX
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS020080-001Dec 28, 1992APRXYesYes► Subscribe► Subscribe
Glaxosmithkline
IMITREX
sumatriptan succinate
TABLET;ORAL020132-002Jun 1, 1995ABRXYesNo► Subscribe► Subscribe
Glaxosmithkline
IMITREX STATDOSE
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS020080-002Feb 1, 2006ABRXYesYes► Subscribe► Subscribe
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-002Aug 26, 1997DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: IMITREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-003Aug 26, 19975,037,845*PED► Subscribe
Glaxosmithkline
IMITREX
sumatriptan succinate
TABLET;ORAL020132-002Jun 1, 19956,368,627*PED► Subscribe
Glaxosmithkline
IMITREX
sumatriptan succinate
TABLET;ORAL020132-001Jun 1, 19956,368,627*PED► Subscribe
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-001Aug 26, 19975,705,520*PED► Subscribe
Glaxosmithkline
IMITREX
sumatriptan succinate
TABLET;ORAL020132-003Jun 1, 19955,863,559*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: IMITREX

Drugname Dosage Strength RLD Submissiondate
sumatriptan succinateInjection6 mg/0.5 mL, 0.5 mL (prefilled syringes)Imitrex5/9/2006
sumatriptan succinateInjection6 mg/0.5 mL, 0.5 mL vialsImitrex10/25/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Chubb
Johnson and Johnson
Colorcon
Chinese Patent Office
Harvard Business School
Express Scripts
McKinsey
Julphar
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot